Department of Health
and Human Services (HHS)
and Human Services (HHS)
October 4, 2021
PAS-21-270 -AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
National Institute on Drug Abuse (NIDA)
The purpose of this Notice is to alert potential applicants to a change in Key Dates in, PAS-21-270, "AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)."
The following sections of PAS-21-270, "AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)."
Currently Reads:
Part 1. Key Dates
Section II. Award Information
Key Dates
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
Not Applicable |
Not Applicable |
January 07, 2022 * |
March 2022 |
May 2022 |
July 2022 |
|
Not Applicable |
Not Applicable |
May 07, 2022 * |
July 2022 |
August 2022 |
December 2022 |
|
Not Applicable |
Not Applicable |
September 07, 2022 * |
November 2022 |
January 2023 |
April 2023 |
|
Not Applicable |
Not Applicable |
January 07, 2023 * |
March 2023 |
May 2023 |
July 2023 |
|
Not Applicable |
Not Applicable |
May 07, 2023 * |
July 2023 |
August 2023 |
December 2023 |
|
Not Applicable |
Not Applicable |
September 07, 2023 * |
November 2023 |
January 2024 |
April 2024 |
|
Not Applicable |
Not Applicable |
January 07, 2024 * |
March 2024 |
May 2024 |
July 2024 |
|
Not Applicable |
Not Applicable |
May 07, 2024 * |
July 2024 |
August 2024 |
December 2024 |
|
Not Applicable |
Not Applicable |
September 07, 2024 * |
November 2024 |
January 2025 |
April 2025 |
Correct Dates: (shown in bold italic)
Part 1. Key Dates
Section II. Award Information
Key Dates
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
Not Applicable |
Not Applicable |
January 07, 2022 * |
March 2022 |
May 2022 |
July 2022 |
|
Not Applicable |
Not Applicable |
May 07, 2022 * |
July 2022 |
October 2022 |
December 2022 |
|
Not Applicable |
Not Applicable |
September 07, 2022 * |
November 2022 |
January 2023 |
April 2023 |
|
Not Applicable |
Not Applicable |
January 07, 2023 * |
March 2023 |
May 2023 |
July 2023 |
|
Not Applicable |
Not Applicable |
May 07, 2023 * |
July 2023 |
October 2023 |
December 2023 |
|
Not Applicable |
Not Applicable |
September 07, 2023 * |
November 2023 |
January 2024 |
April 2024 |
|
Not Applicable |
Not Applicable |
January 07, 2024 * |
March 2024 |
May 2024 |
July 2024 |
|
Not Applicable |
Not Applicable |
May 07, 2024 * |
July 2024 |
October 2024 |
December 2024 |
|
Not Applicable |
Not Applicable |
September 07, 2024 * |
November 2024 |
January 2025 |
April 2025 |
All other aspects of this FOA remain unchanged.
Richard A. Jenkins, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: jenkinsri@mail.nih.gov
Yu (Woody) Lin, MD, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1318
Email: ylin1@nida.nih.gov
Raul N. Mandler, MD
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-2541
Email: mandlerr@mail.nih.gov